Ro 3-4787, a new β-adrenoceptor blocking agent: Studies in normal volunteers

Area of Science:

• Pharmacology
• Cardiovascular Physiology

Background:

• Beta-adrenoceptor blocking agents are crucial for managing cardiovascular conditions.
• Evaluating novel beta-blockers requires rigorous assessment of their efficacy and pharmacokinetic profiles.

Purpose of the Study:

• To investigate the pharmacokinetic and pharmacodynamic properties of a new beta-adrenoceptor blocking agent, Ro 3-4787.
• To compare the efficacy of Ro 3-4787 with propranolol in reducing exercise-induced heart rate.

Main Methods:

• Oral administration of Ro 3-4787 to resting subjects to determine peak plasma levels.
• Intravenous administration of Ro 3-4787 to assess the dose-response relationship with heart rate during exercise.
• A double-blind study comparing Ro 3-4787 and propranolol in normal subjects during exercise.

Main Results:

• Oral administration of 20 mg Ro 3-4787 in a fasting state resulted in peak plasma levels of 106.2 ± 15.5 ng/ml.
• A dose-dependent reduction in exercise heart rate was observed with intravenous Ro 3-4787.
• Ro 3-4787 and propranolol exhibited comparable efficacy in attenuating exercise heart rate at tested doses.
• An inverse correlation was found between pre-exercise plasma drug levels and exercise heart rate for both agents.

Conclusions:

• Ro 3-4787 is an effective oral beta-adrenoceptor blocking agent.
• The new agent, Ro 3-4787, shows comparable efficacy to propranolol in reducing exercise heart rate.
• Plasma levels of Ro 3-4787 correlate inversely with exercise heart rate, suggesting dose-proportional cardiovascular effects.